Skip to main content

Advertisement

SpringerLink
Log in

Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Severe infection is life-threatening in children with hematologic malignancies and its treatment is challenging because of an increasing number of multidrug-resistant pathogens. Tigecycline has an expanded antibacterial activity spectrum; some successful cases of tigecycline treatment have been reported in the literature. Objective To examine the efficacy and safety of tigecycline in children. Setting Department of hematologic malignancies in a tertiary hospital. Method A retrospective chart review from May 1, 2012 to May 1, 2017. The patients were identified by the hospital information system and a custom-made Microsoft Excel 2007 database of patients was created to record demographic and medical data. Main outcome measure Efficacy and safety of tigecycline use in severe infection children with hematologic malignancies. Results Thirty-seven patients were enrolled and the predominant diagnosis was acute lymphoblastic leukemia. The median duration of tigecycline therapy was 9 days. Most prescriptions were empirical. Eighteen patients received a maintenance dose of 2 mg/kg q12 h, without a loading dose. Sulperazone was the most frequently prescribed concomitant drug. At the end of tigecycline therapy, improvement was observed in 48.7% of cases. After treatment, interleukin-10 levels notably decreased. The only reported adverse event was a case of tooth discoloration. Conclusion Tigecycline can be used as salvage therapy in children with hematologic malignancy and seems tolerable. Prospective controlled studies are required to definitively evaluate the efficacy and safety of tigecycline in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Fiser RT, West NK, Bush AJ, Sillos EM, Schmidt JE, Tamburro RF. Outcome of severe sepsis in pediatric oncology patients. Pediatr Crit Care Med. 2005;6(5):531–6.

    Article  Google Scholar 

  2. Averbuch D, Avaky C, Harit M, Stepensky P, Fried I, Ben-Ami T, et al. Non-fermentative gram-negative rods bacteremia in children with cancer: a 14-year single-center experience. Infection. 2017;45(3):327–34. https://doi.org/10.1007/s15010-017-0988-1.

    Article  CAS  PubMed  Google Scholar 

  3. Purdy J, Jouve S, Yan JL, Balter I, Dartois N, Cooper CA, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8–11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther. 2012;34(2):496–507 e1. https://doi.org/10.1016/j.clinthera.2011.12.010.

    Article  CAS  PubMed  Google Scholar 

  4. Wyeth Pharmaceuticals Inc. asoPI. TYGACIL- tigecycline injection, powder, lyophilized, for solution. 2005. http://labeling.pfizer.com/showlabeling.aspx?id=491. Accessed 02 Apr 2018.

  5. Dinleyici EC, Yargic ZA, Bor O, Kiremitci A, Durmaz G. Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;55(2):349–51. https://doi.org/10.1002/pbc.22527.

    Article  PubMed  Google Scholar 

  6. Foresti S, Di Bella S, Rovelli A, Sala A, Verna M, Bisi L, et al. Tigecycline lock therapy for catheter-related bloodstream infection caused by KPC-producing Klebsiella pneumoniae in two pediatric hematological patients. Antimicrob Agents Chemother. 2015;59(12):7919–20. https://doi.org/10.1128/AAC.01855-15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Maximova N, Zanon D, Verzegnassi F, Granzotto M. Neutrophils engraftment delay during tigecycline treatment in 2 bone marrow-transplanted patients. J Pediatr Hematol Oncol. 2013;35(1):e33–7. https://doi.org/10.1097/MPH.0b013e318279eec2.

    Article  CAS  PubMed  Google Scholar 

  8. Tugcu D, Turel O, Aydogan G, Akcay A, Salcioglu Z, Akici F, et al. Successful treatment of multiresistant Achromobacter xylosoxidans bacteremia in a child with acute myeloid leukemia. Ann Saudi Med. 2015;35(2):168–9. https://doi.org/10.5144/0256-4947.2015.168.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Takeda T, Hatae Y, Nakadate H, Fujita K, Suzuki Y, Wagatsuma Y, et al. A multi-institutional study on the efficacy and toxicity of imipenem/cilastatin sodium in severe infections complicating hematological diseases and cancers in children. Study group of infectious diseases in pediatric hematology/oncology in Hokkaido. Jpn J Antibiot. 1993;46(5):388–96.

    CAS  PubMed  Google Scholar 

  10. Zengin E, Sarper N, Kilic SC. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatr Hematol Oncol. 2011;28(4):311–20. https://doi.org/10.3109/08880018.2011.557144.

    Article  CAS  PubMed  Google Scholar 

  11. Schwab KS, Hahn-Ast C, Heinz WJ, Germing U, Egerer G, Glasmacher A, et al. Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection. 2014;42(1):97–104. https://doi.org/10.1007/s15010-013-0524-x.

    Article  CAS  PubMed  Google Scholar 

  12. Yagnik RM, Benzeroual KE. Tigecycline prevents LPS-induced release of pro-inflammatory and apoptotic mediators in neuronal cells. Toxicol Vitro. 2013;27(2):686–93. https://doi.org/10.1016/j.tiv.2012.11.015.

    Article  CAS  Google Scholar 

  13. Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, Gomez AM, et al. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2009;53(4):1546–51. https://doi.org/10.1128/aac.00979-08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. von Seth M, Sjolin J, Larsson A, Eriksson M, Hillered L, Lipcsey M. Effects of tigecycline and doxycycline on inflammation and hemodynamics in porcine endotoxemia: a prospective, randomized, and placebo-controlled trial. Shock. 2015;43(6):604–11. https://doi.org/10.1097/SHK.0000000000000351.

    Article  CAS  Google Scholar 

  15. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–9. https://doi.org/10.1093/jac/dkl403.

    Article  CAS  PubMed  Google Scholar 

  16. Iosifidis E, Violaki A, Michalopoulou E, Volakli E, Diamanti E, Koliouskas D, et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatr Infect Dis Soc. 2017;6(2):123–8. https://doi.org/10.1093/jpids/piw009.

    Article  Google Scholar 

  17. Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. Acta Paediatr. 2016;105(10):e480–4. https://doi.org/10.1111/apa.13516.

    Article  CAS  PubMed  Google Scholar 

  18. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents. 2008;32(1):29–32. https://doi.org/10.1016/j.ijantimicag.2008.02.016.

    Article  CAS  PubMed  Google Scholar 

  19. Prot-Labarthe S, Youdaren R, Benkerrou M, Basmaci R, Lorrot M. Pediatric acute pancreatitis related to tigecycline. Pediatr Infect Dis J. 2010;29(9):890–1. https://doi.org/10.1097/INF.0b013e3181e83a85.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Chanchan Hu and Lingfang Liang for their help with data collection. We also thank Professor Yongmin Tang in the Hematology department of our hospital for his advice.

Funding

This study was supported in part by grants from the Zhejiang Medical and Health Science and Technology Plan Project (2007B119), the Zhejiang Medical and Health Science and Technology Plan Project (2012KYB119), and the Natural Science Foundation of Zhejiang Province (LY12H19006).

Conflicts of interest

There are no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Children’s Hospital Zhejiang University School of Medicine, No. 57, Zhugan Road, Hangzhou, 310003, China

    Shupeng Lin

  2. Department of Pediatric Intensive Care Unit, Children’s Hospital Zhejiang University School of Medicine, No. 3333, Binsheng Road, Hangzhou, 310052, China

    Chenmei Zhang & Sheng Ye

Authors
  1. Shupeng Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chenmei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sheng Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheng Ye.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, S., Zhang, C. & Ye, S. Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies. Int J Clin Pharm 40, 1030–1036 (2018). https://doi.org/10.1007/s11096-018-0690-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-018-0690-0

Keywords

Search

Navigation